oncology
Medicines

Fast-tracked cancer drugs remain in use despite negative confirmatory trials

Some oncology drugs that are granted fast track approval continue to be used for years despite a lack of evidence from confirmatory trials, new research shows. A third of cancer drugs given accelerated approval by the US FDA but which then fail to demonstrate benefit in confirmatory post-approval trials, stay approved regardless, according to a ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic